Literature DB >> 24850292

Low frequency of calreticulin mutations in MDS patients.

M Heuser1, V Panagiota1, C Koenecke1, B Fehse2, H Alchalby2, A Badbaran2, R Shahswar1, M Stadler1, M Eder1, G Göhring3, A Trummer1, T Schroeder4, G Kobbe4, C Thiede5, U Platzbecker5, B Schlegelberger3, N Kroeger2, A Ganser1, F Thol1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24850292     DOI： 10.1038/leu.2014.165

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Analysis of NUP98/NSD1 translocations in adult AML and MDS patients.

Authors:  F Thol; B Kölking; I H I Hollink; F Damm; M M van den Heuvel-Eibrink; C Michel Zwaan; G Bug; O Ottmann; K Wagner; M Morgan; W K Hofmann; G Göhring; B Schlegelberger; J Krauter; A Ganser; M Heuser
Journal:  Leukemia       Date:  2012-08-29       Impact factor: 11.528

2.  SETBP1 mutation analysis in 944 patients with MDS and AML.

Authors:  F Thol; K J Suchanek; C Koenecke; M Stadler; U Platzbecker; C Thiede; T Schroeder; G Kobbe; S Kade; P Löffeld; S Banihosseini; G Bug; O Ottmann; W-K Hofmann; J Krauter; N Kröger; A Ganser; M Heuser
Journal:  Leukemia       Date:  2013-05-07       Impact factor: 11.528

3.  Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Authors:  V Panagiota; F Thol; B Markus; B Fehse; H Alchalby; A Badbaran; U Lehmann; C Koenecke; R Shahswar; A Chaturvedi; M Stadler; M Eder; G Göhring; M Koenigsmann; A Kloos; A Trummer; T Schroeder; G Kobbe; C Thiede; U Platzbecker; B Schlegelberger; H-H Kreipe; A Ganser; N Kröger; M Heuser
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

4.  Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis.

Authors:  J Broséus; E Lippert; A S Harutyunyan; S Jeromin; E Zipperer; L Florensa; J D Milosevic; T Haferlach; U Germing; E Luño; S Schnittger; R Kralovics; F Girodon
Journal:  Leukemia       Date:  2014-01-30       Impact factor: 11.528

5.  Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome.

Authors:  H-A Hou; Y-Y Kuo; W-C Chou; P-H Chen; H-F Tien
Journal:  Leukemia       Date:  2014-02-17       Impact factor: 11.528

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  Modulation of gene expression by calreticulin binding to the glucocorticoid receptor.

Authors:  K Burns; B Duggan; E A Atkinson; K S Famulski; M Nemer; R C Bleackley; M Michalak
Journal:  Nature       Date:  1994-02-03       Impact factor: 49.962

8.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
View more
  3 in total

1.  The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.

Authors:  Jingyi Wang; Jianguo Hao; Na He; Chunyan Ji; Daoxin Ma
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

2.  CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.

Authors:  Tanja Belcic Mikic; Tadej Pajic; Matjaz Sever
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

Review 3.  The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.

Authors:  Tanja Belčič Mikič; Tadej Pajič; Samo Zver; Matjaž Sever
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.